Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe

  • Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs

  • Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients

  • Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network

Basel, May 18, 2021 — …

/by

Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment

  • Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999
  • With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly half over the same timeframe1  
  • Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance

The digital press …

/by
Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
  • Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs
     
  • Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients
     
  • Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network

Basel, May 18, 2021 — Sandoz, a Novartis …

/by